Eli Lilly: favorable data in Crohn's disease

(CercleFinance.com) - On Monday, Eli Lilly reported favorable one-year data from a Phase 3 study of mirikizumab in Crohn's disease.


According to the US pharma group, 58.2% of treated patients showed an inflammatory response after 52 weeks of treatment, compared with 48.8% for J&J's Stelara.

Based on these results, Lilly reports that it has submitted marketing applications for its drug, already approved for the treatment of ulcerative colitis (UC), in the US, Europe, Japan and China.

Mirikizumab is a monoclonal antibody also being studied for the treatment of other immune diseases such as psoriasis.


Copyright (c) 2024 CercleFinance.com. All rights reserved.